Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product
February 08 2024 - 7:00AM
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or
“Quoin”), a specialty pharmaceutical company exclusively focused on
the development and commercialization of innovative therapies that
treat rare and orphan diseases, today announced it has filed U.S.
and International patent applications for a novel combination
product as a potential treatment of Netherton Syndrome.
This new product combines a broad spectrum
serine protease inhibitor with an anti-inflammatory agent in a
proprietary topical formulation. Quoin anticipates that patents
arising from these applications will extend to at least 2044.
“As we continue to advance the clinical
development of Quoin’s lead asset for Netherton Syndrome, we are
pursuing opportunities to strengthen our industry-leading position
in this disease space. Today’s announcement further underscores our
commitment to innovation and to the expansion of our intellectual
property portfolio. This novel product concept, formulated as a
topical lotion, addresses the combined roles that serine protease
inhibition and inflammation play in this disease,” said Dr. Michael
Myers, Chief Executive Officer of Quoin.
Quoin is currently enrolling patients in two
clinical trials being conducted under its open Investigational New
Drug (IND) application, evaluating its QRX003 topical lotion as a
potential treatment of Netherton Syndrome. To date, Quoin remains
the only company actively recruiting subjects into NS clinical
trials that are being conducted under an open IND.
To find our more about Quoin’s clinical studies,
please visit http://www.nethertonsyndromeclinicaltrials.com/
About Netherton Syndrome
Netherton Syndrome, a form of Ichthyosis, is a
rare, hereditary skin disorder caused by a mutation in the SPINK5
gene (serine protease inhibitor, Kazal Type 5) that leads to severe
skin barrier defects and recurring infections, as well as a
pronounced predisposition to allergies, asthma, and eczema.
Patients also often suffer from severe dehydration, chronic skin
inflammation and stunted growth.Currently, there is no cure for
Netherton Syndrome, nor are there any approved therapeutic
treatments.
About QRX003QRX003 is a topical
lotion, formulated with a proprietary delivery technology, and
contains a broad- spectrum serine protease inhibitor, whose
mechanism of action is intended to perform the function of a
specific protein, called LEKTI. The absence of LEKTI in Netherton
patients leads to excessive skin shedding resulting in a highly
porous and compromised skin barrier. QRX003 is designed to lead to
a more normalized skin shedding process and the formation of a
stronger and more effective skin barrier.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is an emerging
specialty pharmaceutical company focused on developing and
commercializing therapeutic products that treat rare and orphan
diseases. We are committed to addressing unmet medical needs for
patients, their families, communities and care teams. Quoin’s
innovative pipeline comprises three products in development that
collectively have the potential to target a broad number of rare
and orphan indications, including Netherton Syndrome, Peeling Skin
Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and
others. For more information, go to: www.quoinpharma.com.
Cautionary Note Regarding Forward Looking
Statements
The Company cautions that statements in this
press release that are not a description of historical facts are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words referencing future
events or circumstances such as "expect," "intend," "plan,"
"anticipate," "believe," and "will," among others. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. These forward-looking statements are
based upon the Company’s current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties. More
detailed information about the risks and uncertainties affecting
the Company is contained under the heading "Risk Factors" included
in the Company’s Annual Report on Form 10-K for the fiscal year
ended December 31, 2022 filed with the SEC on March 15, 2023, as
updated by our subsequent filings with the SEC , and in other
filings the Company has made and may make with the SEC in the
future. One should not place undue reliance on these
forward-looking statements, which speak only as of the date on
which they were made. Because such statements are subject to risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. The
Company undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as may be required by
law.For further information, contact:
Quoin Pharmaceuticals Ltd.Michael Myers, Ph.D.,
CEOmmyers@quoinpharma.com
Investor RelationsPCG AdvisoryStephanie
Princesprince@pcgadvisory.com(646) 863-6341
Quoin Pharmaceuticals (NASDAQ:QNRX)
Historical Stock Chart
From Apr 2024 to May 2024
Quoin Pharmaceuticals (NASDAQ:QNRX)
Historical Stock Chart
From May 2023 to May 2024